Kemal Balic
Overview
Explore the profile of Kemal Balic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alkhouri N, Tseng L, Balic K, Mansbach H, Margalit M
Aliment Pharmacol Ther
. 2024 Feb;
59(6):797-798.
PMID: 38401143
No abstract available.
2.
Tyagi P, Patel C, Gibson K, MacDougall F, Pechenov S, Will S, et al.
Pharmaceutics
. 2023 Oct;
15(10).
PMID: 37896196
Oral delivery of peptides and biological molecules promises significant benefits to patients as an alternative to daily injections, but the development of these formulations is challenging due to their low...
3.
Alkhouri N, Lazas D, Loomba R, Frias J, Feng S, Tseng L, et al.
Aliment Pharmacol Ther
. 2023 Sep;
58(10):1005-1015.
PMID: 37718721
Background: An approved therapy for nonalcoholic steatohepatitis (NASH) and fibrosis remains a major unmet medical need. Aim: To investigate the histological and metabolic benefits of pegozafermin, a glycoPEGylated FGF21 analogue,...
4.
Tseng C, Balic K, Charlton R, Margalit M, Mansbach H, Savic R
Clin Pharmacol Ther
. 2023 Sep;
114(6):1323-1331.
PMID: 37696614
Pegozafermin is a long-acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21) in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. In a phase Ib/IIa placebo-controlled, double-blind,...
5.
Pechenov S, Revell J, Will S, Naylor J, Tyagi P, Patel C, et al.
Sci Rep
. 2021 Nov;
11(1):22521.
PMID: 34795324
Peptide therapeutics are increasingly used in the treatment of disease, but their administration by injection reduces patient compliance and convenience, especially for chronic diseases. Thus, oral administration of a peptide...
6.
Pegram M, Hamilton E, Tan A, Storniolo A, Balic K, Rosenbaum A, et al.
Mol Cancer Ther
. 2021 May;
20(8):1442-1453.
PMID: 34045233
MEDI4276 is a biparatopic tetravalent antibody targeting two nonoverlapping epitopes in subdomains 2 and 4 of the HER2 ecto-domain, with site-specific conjugation to a tubulysin-based microtubule inhibitor payload. MEDI4276 demonstrates...
7.
Huang Y, Del Nagro C, Balic K, Mylott Jr W, Ismaiel O, Ma E, et al.
Anal Chem
. 2020 May;
92(16):11135-11144.
PMID: 32459957
Complex biotherapeutic modalities, such as antibody-drug conjugates (ADC), present significant challenges for the comprehensive bioanalytical characterization of their pharmacokinetics (PK) and catabolism in both preclinical and clinical settings. Thus, the...
8.
Kuruvilla D, Chia Y, Balic K, Yao N, Kreitman R, Pastan I, et al.
Br J Clin Pharmacol
. 2020 Feb;
86(7):1367-1376.
PMID: 32077130
Aims: To characterize the pharmacokinetics (PK) of moxetumomab pasudotox, an anti-CD22 recombinant immunotoxin, in adults with relapsed or refractory hairy cell leukaemia, we examined data from a phase 1 study...
9.
Shah N, Bhojwani D, August K, Baruchel A, Bertrand Y, Boklan J, et al.
Pediatr Blood Cancer
. 2020 Jan;
67(5):e28112.
PMID: 31944549
Background: In a multicenter phase 1 study of children with relapsed/refractory acute lymphoblastic leukemia (ALL), moxetumomab pasudotox, an anti-CD22 immunotoxin, demonstrated a manageable safety profile and preliminary evidence of clinical...
10.
Kreitman R, Dearden C, Zinzani P, Delgado J, Karlin L, Robak T, et al.
Leukemia
. 2018 Jul;
32(8):1768-1777.
PMID: 30030507
This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study...